文献速递药物不良反应与药物警戒

美国风险评价与缓解策略中确保安全使用要素的纵向分析:2008至2022年REMS修改情况

US Risk Evaluation and Mitigation Strategies with Elements to Assure Safe Use: A Longitudinal Analysis of REMS Modifications (2008-2022).
PubMed 文献 · Drug Saf · 2026-03-24

本研究基于FDA公开数据,对2008至2022年批准的100个含确保安全使用要素(ETASU)的REMS项目进行回顾性纵向分析,按药物类别归并为67个REMS类。中位随访7.4年,结果显示REMS修改常见,中位每年每类1.2次修改,首次修改中位时间15.4个月,96%的REMS类至少发生一次修改。

要点

  • REMS修改常见,中位每年每类1.2次,首次修改中位15.4个月。
  • 96%的REMS类在研究结束时至少有一次修改。
  • 修改类型以REMS目标和/或设计变更及REMS材料变更最常见。

核心结论

  • REMS修改常见,反映其能响应新证据并适应医疗实践变化。

研究设计与样本

  • 回顾性纵向病例系列研究,纳入2008年1月1日至2022年12月31日FDA批准的100个含ETASU的REMS项目,归并为67个REMS类。
  • 中位随访7.4年(IQR 2.3-11.6),依据FDA指南将修改分为重大或轻微。

主要发现

  • 每年新批准REMS类的中位数为4个,2017至2022年REMS仅与产品批准同时引入。
  • 每年每REMS类修改中位数为1.2次(IQR 0.7-1.6),共671次修改、364个独特日期。
  • 首次修改中位时间15.4个月(IQR 6.9-25.8),不因索引REMS批准时间而异。
  • 96%(n=64)的REMS类在研究结束时至少有一次修改,修改数量与新增REMS类批准数量比为17:1。
  • 最常见修改类型为REMS目标和/或设计变更(n=221)及REMS材料变更(n=167)。

关键数值与推荐

  • 2008至2012年批准的32个REMS类中,约一半(n=14)在研究结束时演变为共享系统REMS,三分之一(n=10)被解除,解除中位时间7.0年(IQR 4.7-7.2)。

临床怎么用

  • 临床药学智能体应关注REMS修改动态,及时更新用药安全信息。
  • 对于高风险药物,需依据REMS最新要求调整患者监测和材料使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Risk evaluation and mitigation strategies (REMS) are risk management healthcare interventions required by the US Food and Drug Administration (FDA) for certain prescription medicines with serious safety concerns to protect public health and ensure that the benefits outweigh its risks. REMS are expected to evolve over a drug's lifecycle on the basis of new pharmacovigilance evidence and changing healthcare delivery context. OBJECTIVE: The aim of this study is to characterize the frequency and types of REMS modifications over time to inform health policy and pharmacovigilance practice. METHODS: A retrospective longitudinal case series study was conducted using publicly available data on program characteristics and change history from the FDA's public website (REMS@FDA). All REMS programs with elements to assure safe use (ETASU; N = 100) approved by the FDA between 1 January 2008 and 31 December 2022 were linked longitudinally into "REMS Classes" based on common drug class and/or moiety (N = 67). Median follow-up per program was 7.4 (interquartile range [IQR] 2.3-11.6) years after the index REMS approval. Type of REMS modification was coded and categorized as major or minor using the FDA's guidance to the industry. Frequency and type of modification and time to first major modification were assessed. RESULTS: The median number of new REMS Classes approved per year was four. In the last 5 years of observation (2017-2022), REMS were being exclusively introduced concurrently with product approval. The median number of modifications per year per REMS class was 1.2 (IQR 0.7-1.6), representing 671 modifications and 364 unique dates. The median time to first modification was 15.4 (IQR 6.9-25.8) months and did not vary by when the index REMS was approved. Of the REMS classes, 96% (n = 64) had at least one modification by end of observation. As the cumulative number of REMS classes increased over time, modifications to approved REMS classes outpaced the approval of new REMS classes 17:1. The most common types of modifications were changes to REMS goals and/or design (n = 221) and changes to REMS materials (n = 167). However, no clear patterns were observed to suggest a specific type of early modification was more common than another. Among the 32 REMS classes approved in the first 5 years following the FDA Amendments Act of 2007 (FDAAA; 2008-2012), approximately one half (n = 14) had evolved to a shared system REMS by end of observation and one third (n = 10) had been released (median time to release 7.0 years, IQR 4.7-7.2 years). CONCLUSIONS: REMS modifications were common and demonstrated responsiveness to new evidence about the drug and adaptation to changing patterns of healthcare delivery within a learning health system.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Morrato EH, Campagna EJ, LaCivita C, et al. US Risk Evaluation and Mitigation Strategies with Elements to Assure Safe Use: A Longitudinal Analysis of REMS Modifications (2008-2022). Drug Saf. 2026. PMID: 41874837. doi:10.1007/s40264-026-01654-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。